Organisation Breast Cancer Trials (BCT) Health Data Australia Contributor Records Viewed: [[ro.stat.viewed]] Click to explore relationships graph Help Related Data $relation_to_title = []; $dupes = 0;?> Funds A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA (BCT 1901 CAPTURE) Funds A phase II study evaluating a decision aid for women considering neoadjuvant systemic therapy for operable invasive breast cancer (ANZ 1301 DOMINO) Funds A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab (BCT 1702 CHARIOT) isRelatedTo A phase II trial evaluating the efficacy and safety of epirubicin and cyclophosphamide (EC) followed by docetaxel with gemcitabine (DG) (+trastuzumab if HER2-positive) as neoadjuvant chemotherapy for women with large operable or locally advanced breast carcinoma (ANZ 0502 NeoGem) Funds A phase II, randomised, non-comparative two-arm trial of neoadjuvant chemotherapy plus either olaparib or olaparib + durvalumab in young, pre-menopausal women with HRD-enriched, HR-positive, HER2-negative early breast cancer (BCT 2301 OLIO). View all 16 related data User Contributed Tags Login to tag this record with meaningful keywords to make it easier to discover Identifiers ROR : ror.org/00j1vsg87 Saved to MyRDA Save to MyRDA
Click to explore relationships graph Help Related Data $relation_to_title = []; $dupes = 0;?> Funds A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA (BCT 1901 CAPTURE) Funds A phase II study evaluating a decision aid for women considering neoadjuvant systemic therapy for operable invasive breast cancer (ANZ 1301 DOMINO) Funds A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab (BCT 1702 CHARIOT) isRelatedTo A phase II trial evaluating the efficacy and safety of epirubicin and cyclophosphamide (EC) followed by docetaxel with gemcitabine (DG) (+trastuzumab if HER2-positive) as neoadjuvant chemotherapy for women with large operable or locally advanced breast carcinoma (ANZ 0502 NeoGem) Funds A phase II, randomised, non-comparative two-arm trial of neoadjuvant chemotherapy plus either olaparib or olaparib + durvalumab in young, pre-menopausal women with HRD-enriched, HR-positive, HER2-negative early breast cancer (BCT 2301 OLIO). View all 16 related data User Contributed Tags Login to tag this record with meaningful keywords to make it easier to discover Identifiers ROR : ror.org/00j1vsg87